CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Abdullah Alajati(University Hospital Bonn), Andrea Alimonti(Veneto Institute of Molecular Medicine)
Cited by 45
Related Papers
Cellular Senescence: Aging, Cancer, and Injury
|Physiological Reviews|2019|1.3k
Subtle variations in Pten dose determine cancer susceptibility
|Nature Genetics|2010|579
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
|Journal of Clinical Investigation|2018|209